Brought to you by 
Rexahn enters trial collaboration with Merck for breast cancer tx
25 Oct 2021
Executive Summary
Merck & Co. Inc. and Rexahn Pharmaceuticals Inc. penned an agreement to study the combination of Rexahn’s RX5902 (supinoxin) with Merck’s Keytruda (pembrolizumab) as a potential therapy for metastatic triple negative breast cancer (TNBC).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com